Arabic Arabic English English French French German German
dark

Wugen Raises $172 Million to Advance Clinical Stage Memory NK Cell Platform, Progress Best-In-Class AML Program, and Initiate Multiple Solid Tumor Trials

Wugen, Inc. announced the completion of an oversubscribed $172 million Series B financing led by Abingworth and Tybourne Capital Management, and joined by new investors Fidelity Management & Research Company, Intermediate Capital Group, Sands Capital, Aisling Capital Management, Alexandria Venture Investments, Velosity Capital and Falcon Edge Capital. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Lexaria Completes Successful Antiviral Drug Molecular Characterization Study With Canada’s National Research Council

Next Post

NLS Pharmaceutics Announces FDA Acceptance of IND Application to Initiate Clinical Trials with Quilience(R) (mazindol ER) to Treat Narcolepsy

Related Posts
Total
0
Share